• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Effect of genomic drift of influenza PCR tests

tetano

Editor, Senior Moderator
J Clin Virol. 2017 Jun 3;93:25-29. doi: 10.1016/j.jcv.2017.05.016. [Epub ahead of print]
[h=1]Effect of genomic drift of influenza PCR tests.[/h] Stellrecht KA[SUP]1[/SUP], Nattanmai SM[SUP]2[/SUP], Butt J[SUP]2[/SUP], Maceira VP[SUP]2[/SUP], Espino AA[SUP]2[/SUP], Castro AJ[SUP]2[/SUP], Landes A[SUP]2[/SUP], Dresser N[SUP]2[/SUP], Butt SA[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Nucleic acid amplification assays have become the method of choice for influenza (Flu) testing due to superior accuracy and faster turnaround time. Although assays are designed to detect highly conserved genomic targets, mutations can influence test sensitivity. Most of the circulating viruses in the United States during the 2014-2015 season were associated with significant genetic drift; however, the effect on testing was unknown.
[h=4]OBJECTIVES AND STUDY DESIGN:[/h] We compared the performance of Prodesse ProFlu+/ProFAST+ (PFlu/PFAST), FilmArray Respiratory Panel (RP), cobas[SUP]?[/SUP] Influenza A/B test (cIAB), and Xpert[SUP]?[/SUP] Flu (Xpt) in a retrospective analysis of consecutive nasopharyngeal specimens received for a two-week period during the winter of 2015. Furthermore, limits of detection (LOD) were determined with six isolates of Flu.
[h=4]RESULTS:[/h] Of the 275 specimens, 63 were positive for FluA by PFAST, 60 were positive by RP, 58 were positive by cIAB and 52 were positive by Xpt. Only a subset of 135 specimens was tested by PFlu, of which 32 were positive. The sensitivity/specificity for PFAST, RP, cIAB, Xpt and PFlu was 100/99.1%, 96.7/99.5%, 91.8/99.1%, 85.2%/100%, and 75.6%/98.9%, respectively. LOD analyses demonstrated assay performance variations were strain associated. Specifically, PFlu's and cIAB's LODs were higher with A/Texas/50/2012-like and A/Switzerland/9715293/2013-like strains, while Xpt's highest LOD was with the Swiss strain.
[h=4]CONCLUSIONS:[/h] Strain-associated assay performance variation is known to occur with other Flu test methods; hence, it is not surprising that such variation would be observed with molecular tests. Careful monitoring and reporting for strain-associated variances are warranted for all test methods.
Copyright ? 2017 Elsevier B.V. All rights reserved.


[h=4]KEYWORDS:[/h] Clades; Diagnostic PCR; Genetic drift; Influenza; Respiratory viruses

PMID: 28600949 DOI: 10.1016/j.jcv.2017.05.016
 
Back
Top Bottom